Merck Life Science – aka MilliporeSigma – will build facilities to increase filtration equipment and membrane capacity at sites in Cork, Ireland. The total investment is split between two facilities in Cork, with a new filtration manufacturing facility being built at Blarney Business Park for €150 million ($160 million) and €290 million being invested in nearby Carrigtwohill for a manufacturing plant supporting the immersion casting of membranes. From Carrigtwohill, the first commercial products will be produced in 2026. “At full…

Repligen has tweaked its guidance in the wake of diminishing COVID-related orders but remains positive going forward due to a “very strong order book” for its base business. For the first quarter 2022, Repligen Corporation reported record revenue of $206.4 million, 45% up on the same period last year. Despite this, the bioprocess vendor has reduced its full year guidance by 4% from $800-$830 million to $770-$800 million due to the fall in COVID-related demand, something expected to continue throughout…

Sanofi has teamed with Formula 1 racing team McLaren to optimise manufacturing efficiencies within its network. The multiyear deal will see Sanofi’s Industrial Affairs team benefit from McLaren Racing team’s digital and analytical expertise tto achieve excellence in manufacturing operations. “Analysis of losses, modelling and simulation of production line scheduling, and specifically product change-overs, will be key areas to maximise performance in Sanofi manufacturing sites,” McLaren said in a press release. Both Sanofi and McLaren Racing “operate in a truly…

MilliporeSigma says the addition of the MAST (Modular Automated Sampling Technology) platform will help its customers optimize their bioprocesses and speed up development time. Lonza is offloading the platform to bioprocess vendor and fellow contract manufacturer MilliporeSigma – the life sciences service division of Germany’s Merck – for an undisclosed fee. The technology provides biomanufacturers near real-time sampling and analysis of bioreactors, the results of which can be used to deliver a range of analytical devices measuring titer, metabolites, and…

Synthetic biology company Evonetix has achieved enzymatic DNA synthesis capability with its thermally controlled synthesis chemistry, allowing the production of scarless DNA sequences. Evonetix is aiming to bring semiconductor technology to DNA synthesis and claims it has achieved enzymatic DNA synthesis through its thermally controlled synthesis chemistry, which is part of a three-year development program supported by Innovated UK and Durham University. The firm said the results demonstrate that its semiconductor array-based platform is compatible with enzymatic and chemical DNA…